WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mentari Therapeutics, Inc. (NASDAQ:MTRI), a clinical-stage biotechnology company developing therapies for migraine prevention, today announced that members of
Mentari is advancing a robust pipeline of biologics for the prevention of migraine, including MT-001 and MT-002, which target clinically validated pathways and have potential to address the two-thirds of people who have
Shares expected to trade on Nasdaq under the ticker symbol "MTRI" commencing November 9, 2026VANCOUVER, BC, Nov. 6, 2026 /PRNewswire/ -- InMed Pharmaceuticals Inc. (which has changed its name to Mentari
